Zacks Analyst Blog Highlights: Hewlett Packard Company, 3Com Corporation, Cisco Systems Inc., Wal-Mart Stores Inc. and GlaxoSmit
WMT | Quote | Chart | News | PowerRating -- Zacks.com announces the list of stocks featured in the Analyst Blog.
Every day the Zacks Equity Research analysts discuss the latest news and
events impacting stocks and the financial markets. Stocks recently
featured in the blog include: Hewlett Packard Company (NYSE: HPQ | Quote | Chart | News | PowerRating),
3Com Corporation (Nasdaq: COMS | Quote | Chart | News | PowerRating),
Cisco Systems Inc. (Nasdaq: CSCO | Quote | Chart | News | PowerRating),
Wal-Mart Stores Inc. (NYSE: WMT | Quote | Chart | News | PowerRating)
and GlaxoSmithKline, plc (NYSE: GSK | Quote | Chart | News | PowerRating).
Get the most recent insight from Zacks Equity Research with the free
Profit from the Pros newsletter: http://at.zacks.com/?id=4579
Here are highlights from Thursday's Analyst Blog:
Hewlett-Packard to Acquire 3Com
Hewlett Packard Company (NYSE: HPQ | Quote | Chart | News | PowerRating)
is planning to take over networking gear maker 3Com Corporation
(Nasdaq: COMS).
The acquisition, valued at $2.7 billion, enables HP to challenge
networking leader Cisco Systems Inc. (Nasdaq: CSCO | Quote | Chart | News | PowerRating)
on its own turf.
HP's current networking products, sold under the ProCurve brand,
generate around $1 billion in annual sales (less than 1% of the
company's total revenue). The product line lacks competitive data
center switches, which makes it hard to take market share from
well-entrenched Cisco.
3Com's expertise is in networking products for data centers, which
supports HP's ProCurve networking equipment. Although the company has
seen better times, it has been beefing up its portfolio
by utilizing its design capabilities in low-cost China. The company is,
therefore, in a position to compete aggressively on price. 3Com's
challenges include its poor brand value in American and European markets
and its weak position in these geographies.
The HP-3Com combination is therefore an ideal fit, in our opinion. If
the deal closes, HP will acquire a new capability overnight, strengthen
its position in China and grow at its competitor's expense. 3Com will
benefit from HP's superior brand value and find a broader market for its
new products.
Wal-Mart Sales Up in U.S., Europe
Wal-Mart Stores Inc. (NYSE: WMT | Quote | Chart | News | PowerRating)
reported strong fiscal third-quarter earnings of 84 cents
per share, which surpassed the Zacks Consensus Estimate of 81 cents.
Earnings grew 9.1% year over year from 77 cents recorded in the year-ago
quarter, and exceeded management's guidance of 78 cents to 82 cents per
share.
Wal-Mart's net sales recorded a growth of 1.1% year over year to $98.7
billion, as a 1.2% expansion in Wal-Mart's U.S. segment coupled with a
1.6% increase in the International segment was partially offset by 0.7%
decline in the Sam's Club segment. The growth in International sales was
driven by robust performance in the U.K., Mexico and Brazil, but was
limited by unfavorable currency fluctuations.
The retailing behemoth, widely considered as a barometer of the
country's economy, said U.S. same-store sales dipped 0.5%
year-over-year, while that for Sam's Club rose by 0.1%.
Glaxo Reports Higher Revenues
GlaxoSmithKline, plc (NYSE: GSK | Quote | Chart | News | PowerRating)
reported third quarter income of 92 cents per American Depository Share
(ADS), 3 cents below the Zacks Consensus Estimate. The company reported earnings
of 94 cents in the year-ago period.
Third quarter 2009 revenue increased 3%, with growth
being driven by strong performances in emerging markets (up 25%), Japan
(up 19%) and Consumer Healthcare (up 8%). We were pleased to see growth
in Consumer Healthcare revenue despite the global slowdown.
Meanwhile, US sales continued to be impacted by generic competition with
revenue declining 12%. Sales of products like Imigran (down 74%),
Lamictal (down 21%) and Requip (down 30%) and Wellbutrin XL (down 81%)
kept declining.
Pharmaceutical product revenue increased 2% with sales being driven by
Advair/Seretide (up 5%) and Relenza. Relenza benefited from continued
orders from several governments for stockpiling.
Want more from Zacks Equity Research? Subscribe to the free Profit from
the Pros newsletter: http://at.zacks.com/?id=5514.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for
the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock
performance. Recommendations and target prices are six-month time
horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of
the latest analysis from Zacks Equity Research. Subscribe to this free
newsletter today: http://at.zacks.com/?id=5516
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was
formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he
could find patterns in stock market data that would lead to superior
investment results. Amongst his many accomplishments was the formation
of his proprietary stock picking system; the Zacks Rank, which continues
to outperform the market by nearly a 3 to 1 margin. The best way to
unlock the profitable stock recommendations and market insights of Zacks
Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas
GUARANTEED to be worth your time! Register for your free subscription to
Profit from the Pros at http://at.zacks.com/?id=4580.
Visit http://www.zacks.com/performance
for information about the performance numbers displayed in this press
release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before making
any investments. Nothing herein should be construed as an offer or
solicitation to buy or sell any security.
SOURCE: Zacks.com
Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
For full details on GlaxoSmithKline (GSK) GSK. GlaxoSmithKline (GSK) has Short Term PowerRatings at TradingMarkets. Details on GlaxoSmithKline (GSK) Short Term PowerRatings is available at This Link.
For full details on Hewlett-Packard Co (HPQ) HPQ. Hewlett-Packard Co (HPQ) has Short Term PowerRatings at TradingMarkets. Details on Hewlett-Packard Co (HPQ) Short Term PowerRatings is available at This Link.
For full details on Wal-Mart Stores Inc (WMT) WMT. Wal-Mart Stores Inc (WMT) has Short Term PowerRatings at TradingMarkets. Details on Wal-Mart Stores Inc (WMT) Short Term PowerRatings is available at This Link.
For full details on Cisco Systems Inc (CSCO) CSCO. Cisco Systems Inc (CSCO) has Short Term PowerRatings at TradingMarkets. Details on Cisco Systems Inc (CSCO) Short Term PowerRatings is available at This Link.
For full details on 3Com Corp (COMS) COMS. 3Com Corp (COMS) has Short Term PowerRatings at TradingMarkets. Details on 3Com Corp (COMS) Short Term PowerRatings is available at This Link.
- Zacks Sell List Highlights: BancorpSouth, Inc., Aetna Inc., GlaxoSmithKline plc and Airgas, Inc. - 02/09/10
- Research and Markets: Cisco Systems Inc - SWOT Framework Analysis - 02/09/10
- 3Com: The Trend Continues Higher (COMS) - 02/09/10
- SmallCapReview.com: Penny Stocks to Watch - NPWZ, PSPW, TCCO, SMDI - 02/09/10
- China Crescent Enterprises, Inc. Finalizes Agenda for Pacific Rim Sales Conference at Le Royal Meridien Shanghai Featuring Hew - 02/09/10
- More News >>


